Publications in collaboration with researchers from Instituto de Biomedicina de Sevilla (13)

2024

  1. Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practice

    Alimentary Pharmacology and Therapeutics, Vol. 59, Núm. 12, pp. 1604-1615

  2. The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis

    Journal of Gastroenterology, Vol. 59, Núm. 7, pp. 586-597

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

  3. Genome-wide epistasis study highlights genetic interactions influencing severity of COVID-19

    European Journal of Epidemiology, Vol. 38, Núm. 8, pp. 883-889

  4. Mechanisms by which the cystic fibrosis transmembrane conductance regulator may influence SARS-CoV-2 infection and COVID-19 disease severity

    FASEB Journal, Vol. 37, Núm. 11

2022

  1. Detailed stratified GWAS analysis for severe COVID-19 in four European populations

    Human Molecular Genetics, Vol. 31, Núm. 23, pp. 3945-3966

  2. Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH)

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 9, pp. 724-734

2020

  1. Erratum to: “Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17–25) (Journal of Hepatology (2020) 73(1) (17–25), (S0168827820301276), (10.1016/j.jhep.2020.02.028))

    Journal of Hepatology

  2. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH

    Journal of Hepatology, Vol. 73, Núm. 1, pp. 17-25

2019

  1. Alcohol-related liver disease. Clinical practice guidelines. Consensus document sponsored by AEEH

    Gastroenterologia y Hepatologia, Vol. 42, Núm. 10, pp. 657-676

2018

  1. Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline

    Gastroenterologia y Hepatologia, Vol. 41, Núm. 5, pp. 328-349

  2. Erratum to «Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline» [Gastroenterol Hepatol. 2018;41(5):328-349] (S0210570518300037) (10.1016/j.gastrohep.2017.12.003))

    Gastroenterologia y Hepatologia